PT1572233E - Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 - Google Patents

Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 Download PDF

Info

Publication number
PT1572233E
PT1572233E PT03789346T PT03789346T PT1572233E PT 1572233 E PT1572233 E PT 1572233E PT 03789346 T PT03789346 T PT 03789346T PT 03789346 T PT03789346 T PT 03789346T PT 1572233 E PT1572233 E PT 1572233E
Authority
PT
Portugal
Prior art keywords
hpv18
hpv16
vaccine against
hpv type
oncogenic hpv
Prior art date
Application number
PT03789346T
Other languages
English (en)
Inventor
Gary Dubin
Bruce Innis
Moncef M Slaoui
M A C Wettendorff
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT1572233E publication Critical patent/PT1572233E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT03789346T 2002-12-20 2003-12-18 Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68 PT1572233E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43503502P 2002-12-20 2002-12-20
US49665303P 2003-08-20 2003-08-20

Publications (1)

Publication Number Publication Date
PT1572233E true PT1572233E (pt) 2011-06-07

Family

ID=32685362

Family Applications (1)

Application Number Title Priority Date Filing Date
PT03789346T PT1572233E (pt) 2002-12-20 2003-12-18 Utilização de hpv16 e hpv18 como vacina contra um ou mais de tipos de hpv oncogénicos 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68

Country Status (29)

Country Link
US (2) US20060251676A1 (pt)
EP (1) EP1572233B1 (pt)
JP (1) JP5475939B2 (pt)
KR (3) KR101361769B1 (pt)
AP (1) AP2005003347A0 (pt)
AR (1) AR042530A1 (pt)
AT (1) ATE503492T1 (pt)
AU (1) AU2003293942B2 (pt)
BE (3) BE2015C067I2 (pt)
BR (1) BR0317544A (pt)
CA (1) CA2510457C (pt)
CY (1) CY1111552T1 (pt)
DE (1) DE60336581D1 (pt)
DK (1) DK1572233T3 (pt)
EA (2) EA009179B1 (pt)
EC (1) ECSP055869A (pt)
HK (1) HK1085378A1 (pt)
IL (1) IL169085A (pt)
IS (1) IS2811B (pt)
MA (1) MA27581A1 (pt)
MX (1) MXPA05006764A (pt)
MY (1) MY144492A (pt)
NO (1) NO20052846L (pt)
NZ (1) NZ540811A (pt)
OA (1) OA13147A (pt)
PL (1) PL215257B1 (pt)
PT (1) PT1572233E (pt)
TW (1) TWI349557B (pt)
WO (1) WO2004056389A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201482B1 (pl) 1998-10-16 2009-04-30 Smithkline Beecham Biolog Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
GB0206360D0 (en) 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
US7858098B2 (en) 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
US7758866B2 (en) 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
WO2005123125A1 (en) * 2004-06-16 2005-12-29 Glaxosmithkline Biologicals S.A. Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52
AU2006236905B2 (en) 2005-04-15 2010-06-03 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods and compositions for producing an enhanced immune response to a human papillomavirus immunogen
KR20080005585A (ko) * 2005-04-26 2008-01-14 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
WO2006114273A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
DK2147926T3 (en) 2007-04-29 2016-11-28 Beijing Wantai Biological Pharmacy Entpr Co Ltd Truncated human papillomavirus type 18 L1 protein
BRPI0811016B1 (pt) 2007-04-29 2021-09-21 Xiamen Innovax Biotech Co., Ltd. Proteína li truncada do papiloma vírus humano tipo 16
AU2010220824A1 (en) * 2009-03-05 2011-10-20 Jenny Colleen Mccloskey Treatment of infection
WO2010147268A1 (ko) * 2009-06-19 2010-12-23 아이진 주식회사 자궁경부암 백신
CN106461667A (zh) 2014-01-31 2017-02-22 乌利塞生物医药公司 用于检测感染及相关病症的生物传感器
CA2965498A1 (en) 2014-10-24 2016-04-28 Hpvvax, Llc. Compositions and uses of a papilloma virus (hpv) vaccine for the treatment of hpv related cancer and skin lesions
US10799574B2 (en) 2014-10-24 2020-10-13 Hpvvax. Llc Method and composition for treating cancer or skin lesion using a vaccine
CA2987864C (en) * 2015-06-02 2020-08-18 Terumo Kabushiki Kaisha Adjuvant composition containing aluminum and vaccine composition containing the same
JP2021514666A (ja) 2018-03-06 2021-06-17 プレシゲン，インコーポレイテッド Ｂ型肝炎ワクチンおよびその使用
EP3762022A4 (en) * 2018-03-06 2022-06-15 Precigen, Inc. VACCINES AGAINST HUMAN PAPILLOMAVIRUS AND USES THEREOF
JP7265563B2 (ja) * 2018-06-04 2023-04-26 シアメン ユニバーシティ ヒトパピローマウイルス１８型のｌ１タンパク質の変異体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332596A1 (de) * 1993-09-24 1995-03-30 Martin Josef Dr Sapp Monoklonale Antikörper
EP1015561B1 (en) 1997-09-05 2006-07-19 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
SI1150712T1 (sl) * 1999-02-05 2009-02-28 Merck & Co Inc Pripravek cepiva proti humanem papiloma virusu
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6908613B2 (en) * 2000-06-21 2005-06-21 Medimmune, Inc. Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
KR20080075560A (ko) * 2000-06-26 2008-08-18 엔벤타 바이오파마슈티컬스 코포레이션 인간 파필로마 바이러스 치료법

Also Published As

Publication number Publication date
MA27581A1 (fr) 2005-10-03
KR101361769B1 (ko) 2014-02-10
WO2004056389A1 (en) 2004-07-08
ATE503492T1 (de) 2011-04-15
IS2811B (is) 2012-11-15
EA200701633A1 (ru) 2007-12-28
PL215257B1 (pl) 2013-11-29
EA200500834A1 (ru) 2006-02-24
TWI349557B (en) 2011-10-01
NZ540811A (en) 2007-03-30
BE2015C067I2 (pt) 2024-08-08
BE2015C069I2 (pt) 2024-08-08
IS7885A (is) 2005-06-09
CA2510457C (en) 2011-12-06
DE60336581D1 (de) 2011-05-12
AU2003293942A1 (en) 2004-07-14
AP2005003347A0 (en) 2005-06-30
BR0317544A (pt) 2005-11-22
KR20120118087A (ko) 2012-10-25
US20060251676A1 (en) 2006-11-09
IL169085A0 (en) 2007-07-04
MY144492A (en) 2011-09-30
HK1085378A1 (en) 2006-08-25
JP2006512413A (ja) 2006-04-13
CA2510457A1 (en) 2004-07-08
EA009179B1 (ru) 2007-12-28
AU2003293942B2 (en) 2009-12-10
AR042530A1 (es) 2005-06-22
NO20052846L (no) 2005-07-13
BE2015C068I2 (pt) 2024-08-08
TW200423957A (en) 2004-11-16
JP5475939B2 (ja) 2014-04-16
KR20120123616A (ko) 2012-11-08
EP1572233A1 (en) 2005-09-14
CY1111552T1 (el) 2015-08-05
DK1572233T3 (da) 2011-06-27
EP1572233B1 (en) 2011-03-30
US20050287161A1 (en) 2005-12-29
MXPA05006764A (es) 2005-09-08
ECSP055869A (es) 2005-09-20
IL169085A (en) 2014-04-30
OA13147A (en) 2006-12-13
PL377710A1 (pl) 2006-02-06
KR20050086924A (ko) 2005-08-30

Similar Documents

Publication Publication Date Title
HK1085378A1 (en) Use of hpv16 and hpv18 as vaccine against one or more of oncogenic hpv type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
AP1872A (en) Virus-like particles of human papillomavirus.
NO2012016I1 (no) Kombinasjon av HPV16 og HPV18 L1 viruslignende partikler
ZA200502618B (en) Human papillomavirus polypeptides and immunogenic compositions
HUS1500060I1 (hu) A HPV16 és HPV18 és a HPV 31, 45 vagy 52 közül legalább egy másik HPV típus elleni vakcina
AU2002252949A1 (en) 2-(Alpha-HYDROXYPENTYL) BENZOATE AND ITS PREPARATION AND USE
IL179138A0 (en) Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31,45, or 52
AU2003271215A8 (en) Vector for anti-hpv vaccine and transformed microorganism by the vector
AU2003290012A1 (en) L2-peptide of the human papillomavirus associated with virus-like particles
SI1572233T1 (sl) Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
GB2383752B (en) Use of strains of the parapox ovis virus against organ fibrosis
GB0200258D0 (en) Detection of human papillomavirus
AU2001285827A1 (en) Use of strains of the parapox ovis virus against organ fibrosis
AU2001285827A2 (en) Use of strains of the parapox ovis virus against organ fibrosis
AUPR790901A0 (en) Inactivation of papillomavirus
AU2002320079A1 (en) Vaccines, immunotherapeutics and methods of using the same
AU2002318385A1 (en) Geminin and orc3n inhibit replication of herpesviruses, papillomaviruses, and polyomaviruses
AU2003289640A1 (en) Tricyclacetalactonin, Preparation and Use there of
AU2002322573A1 (en) Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin
AU2003902724A0 (en) Single-use container, closure, and serving implement
AUPS171002A0 (en) Viral variants, detection and use